Characteristics of patients with CTCL, treatment, and experimental assay performed
| Patient ID . | Assay . | Sex . | Race . | CTCL type . | Stage at sample procurement . | Treatment at time of collection . |
|---|---|---|---|---|---|---|
| MF1 | Flow cytometry | M | White | MF | IA | Imiquimod |
| MF2 | Flow cytometry | F | White | MF | IA | Desoximetasone |
| MF3 | Flow cytometry | M | White | MF | IA | Clobetasol |
| U16-2023 | Cytotoxicity assay | M | White | MF | IB | PUVA, triamcinolone, imiquimod |
| U16-2101 | Cytotoxicity assay | M | White | MF | IB | Bexarotene |
| U16-2102 | Cytotoxicity assay | M | White | MF | IB | Bexarotene |
| U16-2225 | Cytotoxicity assay | M | White | MF | IIB | Gemcitabine/doxorubicin |
| U16-2228 | Cytotoxicity assay | M | White | MF | IIB | Bexarotene |
| U16-2237 | Cytotoxicity assay | F | African American | MF | IA | Topical steroids |
| U17-0092 | Cytotoxicity assay | M | White | MF | IB | Bexarotene |
| U17-0093 | Cytotoxicity assay | F | White | MF | IB | Topical steroids |
| U17-0094 | Cytotoxicity assay | M | White | MF | IA | nbUVB |
| U17-0095 | Cytotoxicity assay/RNA sequencing | M | White | MF | IA | Bexarotene |
| U17-0253 | Cytotoxicity assay/RNA sequencing | F | White | MF | IA | Topical bexarotene |
| U17-0254 | Cytotoxicity assay/RNA sequencing | F | White | MF | IB | nbUVB |
| U17-0314 | Flow cytometry | F | African American | SS | IVB | Romidepsin |
| U17-0315 | Flow cytometry | F | White | MF | 1A | Topical steroids |
| U17-0316 | Flow cytometry | F | White | MF | IB | Valchlor gel |
| U17-0341 | Flow cytometry | M | White | MF | 1A | Oral or topical bexarotene |
| U17-0342 | Flow cytometry | M | White | MF | 1A | Mechlorethamine gel, clobetasol |
| U17-0343 | Flow cytometry | M | White | MF | 1A | Mechlorethamine gel, TAC |
| U17-0350 | Flow cytometry | F | African American | MF | IA | Topical steroids |
| U17-0352 | Flow cytometry | F | White | MF | IA | Oral bexarotene |
| U17-0353 | Flow cytometry | M | White | MF | 1B | Interferon, nbUVB, TAC, clobetasol |
| U17-0543 | RNA sequencing | M | White | SS | 1VA | Romidepsin, IPH 4102 |
| U17-0593 | RNA sequencing | M | White | MF | 1B | Gemcitabine/ doxorubicin |
| U17-0594 | RNA sequencing | M | White | SS | IVA1 | Topical steroids |
| U17-0595 | RNA sequencing | M | White | MF | IA | TAC |
| U17-1613 | Phospho-specific flow cytometry | F | White | MF | IIB | Brentuximab |
| U17-1614 | Phospho-specific flow cytometry | M | White | SS | 1VA2 | Bendamustine + brentuximab vedotin |
| U17-1615 | Phospho-specific flow cytometry | M | White | MF | IA | nbUVB |
| U17-1616 | Phospho-specific flow cytometry | F | White | MF | 1B | TAC, nbUVB |
| U17-1654 | Phospho-specific flow cytometry | M | White | MF | 1A | Clobetasol |
| U17-1657 | Phospho-specific flow cytometry | M | White | MF | IA | TAC |
| U17-1658 | Phospho-specific flow cytometry | M | White | MF | 1A | TAC, topical imiquimod |
| U17-1649 | Phospho-specific flow cytometry | F | White | MF | 1B | Romidepsin |
| U17-1651 | Phospho-specific flow cytometry | F | White | MF | 1B | nbUVB, TAC, interferon, oral bexarotene |
| U17-1652 | Phospho-specific flow cytometry | F | White | MF | IA | Topical bexarotene |
| U17-1653 | Phospho-specific flow cytometry | M | White | MF | IA | TAC |
| U17-1819 | Phospho-specific flow cytometry | M | White | MF | IA | Romidepsin |
| U17-1936 | Phospho-specific flow cytometry | M | White | SS | IVA | Bexarotene and interferon |
| U17-1937 | Phospho-specific flow cytometry | M | White | SS | IIIA | None |
| U17-1938 | Phospho-specific flow cytometry | F | White | MF | 1A | None |
| Patient ID . | Assay . | Sex . | Race . | CTCL type . | Stage at sample procurement . | Treatment at time of collection . |
|---|---|---|---|---|---|---|
| MF1 | Flow cytometry | M | White | MF | IA | Imiquimod |
| MF2 | Flow cytometry | F | White | MF | IA | Desoximetasone |
| MF3 | Flow cytometry | M | White | MF | IA | Clobetasol |
| U16-2023 | Cytotoxicity assay | M | White | MF | IB | PUVA, triamcinolone, imiquimod |
| U16-2101 | Cytotoxicity assay | M | White | MF | IB | Bexarotene |
| U16-2102 | Cytotoxicity assay | M | White | MF | IB | Bexarotene |
| U16-2225 | Cytotoxicity assay | M | White | MF | IIB | Gemcitabine/doxorubicin |
| U16-2228 | Cytotoxicity assay | M | White | MF | IIB | Bexarotene |
| U16-2237 | Cytotoxicity assay | F | African American | MF | IA | Topical steroids |
| U17-0092 | Cytotoxicity assay | M | White | MF | IB | Bexarotene |
| U17-0093 | Cytotoxicity assay | F | White | MF | IB | Topical steroids |
| U17-0094 | Cytotoxicity assay | M | White | MF | IA | nbUVB |
| U17-0095 | Cytotoxicity assay/RNA sequencing | M | White | MF | IA | Bexarotene |
| U17-0253 | Cytotoxicity assay/RNA sequencing | F | White | MF | IA | Topical bexarotene |
| U17-0254 | Cytotoxicity assay/RNA sequencing | F | White | MF | IB | nbUVB |
| U17-0314 | Flow cytometry | F | African American | SS | IVB | Romidepsin |
| U17-0315 | Flow cytometry | F | White | MF | 1A | Topical steroids |
| U17-0316 | Flow cytometry | F | White | MF | IB | Valchlor gel |
| U17-0341 | Flow cytometry | M | White | MF | 1A | Oral or topical bexarotene |
| U17-0342 | Flow cytometry | M | White | MF | 1A | Mechlorethamine gel, clobetasol |
| U17-0343 | Flow cytometry | M | White | MF | 1A | Mechlorethamine gel, TAC |
| U17-0350 | Flow cytometry | F | African American | MF | IA | Topical steroids |
| U17-0352 | Flow cytometry | F | White | MF | IA | Oral bexarotene |
| U17-0353 | Flow cytometry | M | White | MF | 1B | Interferon, nbUVB, TAC, clobetasol |
| U17-0543 | RNA sequencing | M | White | SS | 1VA | Romidepsin, IPH 4102 |
| U17-0593 | RNA sequencing | M | White | MF | 1B | Gemcitabine/ doxorubicin |
| U17-0594 | RNA sequencing | M | White | SS | IVA1 | Topical steroids |
| U17-0595 | RNA sequencing | M | White | MF | IA | TAC |
| U17-1613 | Phospho-specific flow cytometry | F | White | MF | IIB | Brentuximab |
| U17-1614 | Phospho-specific flow cytometry | M | White | SS | 1VA2 | Bendamustine + brentuximab vedotin |
| U17-1615 | Phospho-specific flow cytometry | M | White | MF | IA | nbUVB |
| U17-1616 | Phospho-specific flow cytometry | F | White | MF | 1B | TAC, nbUVB |
| U17-1654 | Phospho-specific flow cytometry | M | White | MF | 1A | Clobetasol |
| U17-1657 | Phospho-specific flow cytometry | M | White | MF | IA | TAC |
| U17-1658 | Phospho-specific flow cytometry | M | White | MF | 1A | TAC, topical imiquimod |
| U17-1649 | Phospho-specific flow cytometry | F | White | MF | 1B | Romidepsin |
| U17-1651 | Phospho-specific flow cytometry | F | White | MF | 1B | nbUVB, TAC, interferon, oral bexarotene |
| U17-1652 | Phospho-specific flow cytometry | F | White | MF | IA | Topical bexarotene |
| U17-1653 | Phospho-specific flow cytometry | M | White | MF | IA | TAC |
| U17-1819 | Phospho-specific flow cytometry | M | White | MF | IA | Romidepsin |
| U17-1936 | Phospho-specific flow cytometry | M | White | SS | IVA | Bexarotene and interferon |
| U17-1937 | Phospho-specific flow cytometry | M | White | SS | IIIA | None |
| U17-1938 | Phospho-specific flow cytometry | F | White | MF | 1A | None |
nbUVB narrow-band ultraviolet B light therapy; PUVA, psoralen and ultraviolet A (light therapy); Tac, triamcinolone cream.